In a new study, researchers describe the results of a genome-wide screen of Pseudomonas aeruginosa in a yeast, which led to the identification of three potential new Pseudomonas virulence factors. The research paper, entitled “Genome-wide Screen of Pseudomonas aeruginosa in Saccharomyces cerevisiae Identifies New Virulence Factors,” was published in Frontiers in Cellular and…
News
Luanne McKinnon, like many cystic fibrosis (CF) patients, is a determined achiever who lives life to its fullest — even earning a doctorate in art history at age 60. Her story was the subject of a recent profile in The University of Virginia’s online newspaper, UVA Today. McKinnon, who was awarded her PhD…
The Boomer Esiason Foundation (BEF) recently launched an awareness campaign for Team Boomer, its effort to encourage the cystic fibrosis (CF) community to live a healthy and active lifestyle and gets athletes to join the fight. The current initiative includes an EHE International partnership that led to a prominent BEF holiday window display at Rockefeller…
Harvard Assets, a Pennsylvania-based provider of bullion and investment-grade diamond, recently renewed its support to the Cystic Fibrosis Foundation (CFF) and its mission of supporting the development of new drugs to fight cystic fibrosis (CF), improving the quality of life for those with the disease, and ultimately finding a cure. John Tucker,…
Nivalis Therapeutics, Inc., a Boulder, Colorado-based clinical stage pharmaceutical company, announced that the first patient has been dosed in the Phase 2 clinical trial of its lead investigational drug, N91115, a stabilizer of the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The purpose of this double-blind, randomized, placebo-controlled, parallel group study…
Protein interactions could be misdirected in people with cystic fibrosis (CF), causing a loss of normal protein function, according to researchers from the Scripps Research Institute (TSRI) in San Diego, California. The new study, titled “∆F508 CFTR interactome remodelling promotes rescue of cystic fibrosis“ appeared online on Nov. 30, 2015, ahead…
The Cystic Fibrosis Foundation’s 2015 Ultimate Golf Experience, which ran four days beginning on Oct. 21, raised $630,000 towards continuing the organization’s mission of promoting disease research and awareness. Over 200 people attended the tournament at the Ritz-Carlton Dove Mountain resort in Tucson, Arizona. The event was hailed as a success and a source of much-needed…
Ever since High Frequency Chest Wall Oscillation (HFCWO) devices were developed to help patients with cystic fibrosis breathe easier, clinical researchers required appropriate parameters to assess the efficacy of HFCWO-based therapies. It is common practice to look at three main indicators of pulmonary and overall health: mucus clearance,…
A new cystic fibrosis study, showing a high-resolution picture of the fungal microbiome of cystic fibrosis patients’ lungs, has identified a genetic basis for pathogen adaptation in a fungus exposed to bacteria. The study, entitled “Global Analysis of the Fungal Microbiome in Cystic Fibrosis Patients Reveals Loss of Function of…
PTC Therapeutics Inc. has announced the completion of patient enrollment in its second Phase 3 clinical trial of the experimental cystic fibrosis therapy Translarna™. The clinical trial, named ACT CF, is a placebo controlled study designed to evaluate the efficacy of Translarna (ataluren) in patients, age 6 or older, with nonsense…
Your CF Community
Visit the Cystic Fibrosis News Today forums to connect with others in the CF community.